Serum amyloid A and inflammation;Siero amiloide A e flogosi

Biochimica Clinica

Volumn 34, Issue 5, 2010, Pages 326-330

  Obici, Laura ^a   Donadei, Simona ^a   Albertini, Riccardo ^a   Moratti, Remigio ^a   Merlini, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ISOPROTEIN; PROTEOME; SERUM AMYLOID A; SERUM AMYLOID A1; SERUM AMYLOID A2; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; KIDNEY GRAFT REJECTION; LIPID METABOLISM; NEWBORN SEPSIS; POLYMERASE CHAIN REACTION; PROTEOMICS; REVIEW; TISSUE INJURY; TUMOR GROWTH;

EID: 77957684722     PISSN: 03930564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med 1999;37:381-8. (Pubitemid 29218956)
2. Jiang SL, Lozanski G, Samols D, et al. Induction of human serum amyloid A in Hep3B cells by IL-6 and IL-1β involves both transcriptional and post-transcriptional mechanisms. J Immunol 1995;154:825-31.
3. Larson MA, Wei SH, Weber A, et al. Induction of human mammary-associated SAA3 expression by prolactin or lipopolysaccharide. Biochem Biophys Res Commun 2003;301:1030-7. (Pubitemid 36279216)
4. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996;26:427-35.
5. Jahangiri A, de Beer MC, Noffsinger V, et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2009;29:261-7.
6. O'Brien KD, Chait A. Serum amyloid A: The "other" inflammatory protein. Curr Atheroscler Rep 2006;8:62-8.
7. Uhlar C, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999;265:501-23.
8. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64-9. (Pubitemid 30007690)
9. Shah C, Hari-Dass R, Raynes JG. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood 2006;108:1751-7.
10. Obici L, Raimondi S, Lavatelli F, et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61:1435-50.
11. Wu TL, Tsai IC, Chang PY, et al. Establishment of an inhouse ELISA and the reference range for serum amyloid A (SAA). Complementarity between SAA and C-reactive protein as markers of inflammation. Clin Chim Acta 2007;376:72-6.
12. Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998;35:745-53.
13. Melzi d'Eril GV, Anesi A, Maggiore M, et al. Biological variation of serum amyloid A in healthy subjects. Clin Chem 2001;47:1498-9.
14. Lannergard A, Friman G, Ewald U, et al. Serum amyloid A (SAA) protein and high-sensitivity C-reactive protein (hsCRP) in healthy newborn infants and healthy young through elderly adults. Acta Paediatrica 2005;94:1198-202.
15. Lannergard A, Larsson A, Kargsbjerg P, et al. Correlations between serum amyloid A protein and C-reactive protein in infectious diseases. Scand J Clin Lab Invest 2003;63:267-72. (Pubitemid 37006434)
16. Shimetani N, Shimetani K, Mori M. Clinical evaluation of the measurement of serum procalcitonin: comparative study of procalcitonin and serum amyloid A protein in patients with high and low concentrations of serum Creactive protein. Scand J Clin Lab Invest 2004;64:469-74. (Pubitemid 39070624)
17. Arnon S, Litmanovitz I, Regev R, et al. The prognostic virtue of inflammatory markers during late-onset sepsis in preterm infants. J Perinat Med 2004;32:176-80. (Pubitemid 39220541)
18. Mussap M, Fanos C, Pizzini C, et al. Serum amyloid A (SAA) protein compared with C-reactive protein for the evaluation of the acute phase response in preterm newborns: preliminary results. Clin Chem Lab Med 1999;37:389-95.
19. Arnon S, Litmanovitz I, Regev R, et al. Serum amyloid A protein is a useful inflammatory marker during late-onset sepsis in preterm infants. Biol Neonate 2005;87:105-10.
20. Cetinkaya M, Ozkan H, Koksal N, et al. Comparison of serum amyloid A concentrations with those of C-reactive protein and procalcitonin in diagnosis and follow-up of neonatal sepsis in premature infants. J Perinatol 2009;29:225-31.
21. Hartmann A, Eide TC, Fauchald P, et al. Serum amyloid A protein is a clinically useful indicator of acute renal allograft rejection. Nephrol Dial Transplant 1997;12:161-6.
22. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24. (Pubitemid 24247397)
23. Havertake F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
24. Morrow D, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 2000;35:358-62. (Pubitemid 30125525)
25. Kosuge M, Ebina T, Ishikawa T, et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST segment elevation acute coronary syndromes. Circ J 2007;71:186-90. (Pubitemid 46182690)
26. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004;109:726-32.
27. Gutfeld O, Prus D, Ackerman Z, et al. Expression of serum amyloid A in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem 2006;54:63-73.
28. Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009;66:9-26.
29. Cremona M, Calabrò E, Randi G, et al. Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. Cancer 2010;116:1326-35.
30. Cho WC, Yip TT, Cheng WW, et al. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer 2010;102:1731-5.
31. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. New Engl J Med 2007;356:2361-71.